NCT06370585View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

July 25, 2024

Study Completion Date

November 13, 2024

Conditions
Dry Eye DiseaseOcular Surface Disease
Interventions
DRUG

PRO-229

\- Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.

DRUG

Lagricel® Ofteno PF

\- Sodium hyaluronate 0.4%. Ophthalmic solution.

Trial Locations (1)

42070

Asociacion Mexicana para la Investigacion Clinica, Pachuca

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT06370585 - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF | Biotech Hunter | Biotech Hunter